|
| Interactions: | Adenosine
Adverse Effect: adenosine toxicity (hypotension, dyspnea, vomiting) Clinical Management: When dipyridamole is used before adenosine, smaller dose of adenosine may be effective.
Ardeparin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Ardeparin or heparinoid. If this is not possible, patients receiving Ardeparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Dalteparin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Dalteparin or heparinoid. If this is not possible, patients receiving Dalteparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Enoxaparin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Enoxaparin or heparinoid. If this is not possible, patients receiving Enoxaparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Indomethacin
Adverse Effect: Fluid and electrolyte disturbances Clinical Management: Monitor renal function especially in patients with cardiac or vascular problems. Be alert for signs of fluid retention with concurrent use.
Nadroparin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Nadroparin or heparinoid. If this is not possible, patients receiving Nadroparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Reviparin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Reviparin or heparinoid. If this is not possible, patients receiving Reviparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Streptokinase
Adverse Effect: an increased risk of bleeding Clinical Management: Dipyridamole and streptokinase should be used concurrently only when the potential benefit outweighs the risk of bleeding. Observe patients for external bleeding and be alert for signs and symptoms of internal bleeding.
Theophylline
Adverse Effect: False negative thallium imaging results Clinical Management: If possible, discontinue theophylline prior to a dipyridamole-thallium imaging test. |
|
|